Pentagon Directed to Explore Psychedelic Treatment Access for Military
House Armed Services Committee instructs Defense Secretary to study therapeutic pathways following Trump executive order on psychedelics research.
The House Armed Services Committee has instructed Pentagon leadership to examine therapeutic access pathways for psychedelic treatments within military healthcare systems. The directive, embedded in report language accompanying the annual National Defense Authorization Act, references President Trump's April executive order that prioritized psychedelics research for medical applications.
The congressional mandate represents a watershed moment for the psychedelics sector, potentially opening Department of Defense healthcare networks to MDMA, psilocybin, and other controlled substances currently advancing through FDA clinical trials. Military healthcare serves approximately 9.6 million active duty personnel, retirees, and dependents—creating a substantial addressable market for companies developing psychedelic therapeutics.
This development arrives as the psychedelics industry faces regulatory headwinds following FDA's rejection of MDMA-assisted therapy applications earlier this year. Companies like Compass Pathways, developing psilocybin treatments, and smaller players focusing on military PTSD applications could benefit from dedicated Defense Department research funding and streamlined approval processes within military medical systems.
The timing aligns with growing bipartisan recognition that traditional PTSD treatments fail many veterans. Current pharmaceutical interventions show limited efficacy, while veteran suicide rates remain elevated despite decades of conventional therapy approaches. Psychedelic-assisted therapies demonstrate breakthrough potential in clinical settings, with some studies showing sustained remission rates exceeding 60% for treatment-resistant PTSD cases.
Congress appears positioned to accelerate psychedelics integration into federal healthcare systems, bypassing traditional regulatory bottlenecks that have constrained commercial market development. If the Defense Department establishes successful treatment protocols, this framework could influence Veterans Affairs healthcare policies and create precedent for broader federal adoption of psychedelic therapies across government health programs.